XFOR (STOCKS)
X4 Pharmaceuticals, Inc. Common Stock
$3.375000
-0.055000 (-1.60%)
Prev close: $3.430000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Paula S. Ragan, PhD
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $295.10M
- Employees
- 143
- P/E (TTM)
- -0.34
- P/B (TTM)
- 1.40
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.69 | $-0.93 | +0.2443 | +26.15% |
|
Jun 2025 (Q2)
|
$-3.47 | $-4.42 | +0.9548 | +21.58% |
|
Mar 2025 (Q1)
|
$0.04 | $-4.53 | +4.5688 | +100.88% |
|
Dec 2024 (Q4)
|
$-6.00 | $-5.36 | -0.6450 | -12.04% |
Financial Statements
| Revenues | $5.76M |
| Benefits Costs and Expenses | $100.46M |
| Cost Of Revenue | $5.70M |
| Costs And Expenses | $99.72M |
| Gross Profit | $62.00K |
| Nonoperating Income/Loss | $4.10M |
| Operating Expenses | $98.96M |
| Research and Development | $75.90M |
| Operating Income/Loss | -$98.90M |
| Income/Loss From Continuing Operations After Tax | -$95.10M |
| Income/Loss From Continuing Operations Before Tax | -$94.80M |
| Income Tax Expense/Benefit | $299.00K |
| Net Income/Loss | -$95.10M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$95.10M |
| Net Income/Loss Available To Common Stockholders, Basic | -$95.10M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.66 |
| Diluted Earnings Per Share | -$4.66 |
| Basic Average Shares | 251,906,875 |
| Diluted Average Shares | 251,930,017 |
| Assets | $163.56M |
| Current Assets | $132.81M |
| Cash | $122.20M |
| Other Current Assets | $10.61M |
| Noncurrent Assets | $30.75M |
| Fixed Assets | $218.00K |
| Other Non-current Assets | $30.53M |
| Liabilities | $101.94M |
| Current Liabilities | $23.51M |
| Accounts Payable | $5.05M |
| Wages | $8.34M |
| Other Current Liabilities | $10.11M |
| Noncurrent Liabilities | $78.43M |
| Long-term Debt | $75.00M |
| Other Non-current Liabilities | $3.43M |
| Equity | $61.62M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $61.62M |
| Liabilities And Equity | $163.56M |
| Net Cash Flow From Operating Activities | -$103.09M |
| Net Cash Flow From Operating Activities, Continuing | -$103.09M |
| Net Cash Flow From Investing Activities | -$17.32M |
| Net Cash Flow From Investing Activities, Continuing | -$17.32M |
| Net Cash Flow From Financing Activities | $92.67M |
| Net Cash Flow From Financing Activities, Continuing | $92.67M |
| Exchange Gains/Losses | -$34.00K |
| Net Cash Flow | -$27.77M |
| Net Cash Flow, Continuing | -$27.73M |
| Other Comprehensive Income/Loss | -$57.65M |